EU/3/15/1520

About

On 28 July 2015, orphan designation (EU/3/15/1520) was granted by the European Commission to GW Pharma Ltd, United Kingdom, for cannabidiol for the treatment of perinatal asphyxia.

Key facts

Active substance
Cannabidiol
Disease / condition
Treatment of perinatal asphyxia
Date of decision
28/07/2015
Outcome
Positive
Orphan decision number
EU/3/15/1520

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

GW Pharma Ltd
Sovereign House
Vision Park
Chivers Way, Histon
Cambridge CB24 9BZ
United Kingdom
Tel. +44 (0)1223 266 800
Fax +44 (0)1223 235 667
E-mail: medicalinformation@gwpharm.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating